We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+6.26%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.69B
AUM Growth
+$546M
(+11%)
Cap. Flow
+$263M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
11.85%
Holding
1,134
New
196
Increased
491
Reduced
251
Closed
159
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$35.7M |
| 2 |
Merck
MRK
|
+$30.3M |
| 3 |
Microsoft
MSFT
|
+$22.4M |
| 4 |
Yum China
YUMC
|
+$17.6M |
| 5 |
Occidental Petroleum
OXY
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$36.5M |
| 2 |
Intel
INTC
|
+$32.4M |
| 3 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$17.1M |
| 4 |
NVR
NVR
|
+$16.3M |
| 5 |
Deere & Co
DE
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.48% |
| 2 | Financials | 17.92% |
| 3 | Industrials | 13.48% |
| 4 | Consumer Discretionary | 11.28% |
| 5 | Healthcare | 10.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
626
DELISTED
Chimerix, Inc.
CMRX
| $943K | 0.02% |
203,695
+49,287
| +32% | +$234K |
|
627
W.R. Berkley
WRB
$28B
| $925K | 0.02% |
43,554
-79,347
| -65% | -$1.62M |
|
628
Preferred Bank
PFBC
$1.22B
| $923K | 0.02% |
15,710
-1,020
| -6% | -$61.9K |
|
|
SRDX
629
DELISTED
Surmodics
SRDX
| $923K | 0.02% |
32,974
+3,070
| +10% | +$93.7K |
|
|
ASNA
630
DELISTED
Ascena Retail Group, Inc.
ASNA
| $922K | 0.02% |
+19,611
| New | +$826K |
|
631
WesBanco
WSBC
$3.95B
| $913K | 0.02% |
+22,454
| New | +$917K |
|
|
FARO
632
DELISTED
Faro Technologies
FARO
| $909K | 0.02% |
19,340
+6,100
| +46% | +$286K |
|
|
LMNX
633
DELISTED
Luminex Corp
LMNX
| $908K | 0.02% |
46,068
-57,950
| -56% | -$1.21M |
|
634
Seres Therapeutics
MCRB
$48M
| $905K | 0.02% |
+4,461
| New | +$917K |
|
635
STAAR Surgical
STAA
$1.16B
| $901K | 0.02% |
58,160
+47,690
| +455% | +$709K |
|
636
Warrior Met Coal
HCC
$4.23B
| $898K | 0.02% |
35,700
+21,620
| +154% | +$543K |
|
637
Corcept Therapeutics
CORT
$10.2B
| $891K | 0.02% |
49,310
+29,500
| +149% | +$534K |
|
|
TTPH
638
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $890K | 0.02% |
7,060
+1,670
| +31% | +$214K |
|
639
Blackbaud
BLKB
$1.5B
| $888K | 0.02% |
9,400
| – | – |
|
640
Agios Pharmaceuticals
AGIO
$2.16B
| $886K | 0.02% |
+15,500
| New | +$975K |
|
641
Digi International
DGII
$2.52B
| $880K | 0.02% |
92,097
+32,206
| +54% | +$329K |
|
642
Kroger
KR
$34.8B
| $873K | 0.02% |
31,800
-53,420
| -63% | -$1.24M |
|
643
Triumph Financial Inc
TFIN
$1.84B
| $872K | 0.02% |
27,696
+2,670
| +11% | +$84.3K |
|
|
EGIO
644
DELISTED
Edgio, Inc. Common Stock
EGIO
| $872K | 0.02% |
4,942
+3,205
| +185% | +$633K |
|
|
IPHS
645
DELISTED
Innophos Holdings, Inc.
IPHS
| $863K | 0.02% |
+18,462
| New | +$862K |
|
646
Heritage Financial
HFWA
$1.24B
| $862K | 0.02% |
27,982
+2,532
| +10% | +$78K |
|
647
CRA International
CRAI
$1.1B
| $859K | 0.02% |
19,105
+7,685
| +67% | +$337K |
|
648
Spire
SR
$4.92B
| $857K | 0.02% |
11,400
-520
| -4% | -$40.3K |
|
649
Allient
ALNT
$1.47B
| $855K | 0.02% |
38,751
+4,050
| +12% | +$82.3K |
|
650
Park-Ohio Holdings
PKOH
$554M
| $855K | 0.02% |
18,610
+4,400
| +31% | +$197K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2017 Portfolio in Review
As of Q4 2017, Jacobs Levy Equity Management held 1,134 positions worth $5.69B, up 11% from $5.14B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jacobs Levy Equity Management deployed $263M of net new capital in Q4 2017, opening 196 new positions and adding to 491 existing holdings. Its largest new stake was Yum China: 427,927 shares worth $17.1M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $36.5M trimmed.
- Jacobs Levy Equity Management's largest Q4 2017 buy was Yum China: 427,927 shares worth $17.1M.
- Jacobs Levy Equity Management added most to Bristol-Myers Squibb in Q4 2017, an estimated $35.7M increase.
- Jacobs Levy Equity Management's biggest Q4 2017 reduction was Johnson & Johnson, cutting an estimated $36.5M.
- Jacobs Levy Equity Management fully exited Twenty-First Century Fox, Inc. Class A in Q4 2017, selling an estimated $17.1M.
- Jacobs Levy Equity Management's ten largest holdings make up 12% of its $5.69B portfolio in Q4 2017.
- Jacobs Levy Equity Management opened 196 new positions and closed 159 in Q4 2017.
- Jacobs Levy Equity Management's portfolio value rose 11% quarter-over-quarter to $5.69B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.